FDA Vouchers Encourage Drug Companies To Focus On NTDs

NPR: FDA Dangles Golden Ticket To Spur Drugs For Neglected Diseases
“…[T]he approval of the leishmaniasis drug, Impavido, came with a coupon that the company [that produces the drug] can redeem to have any drug it likes moved toward the front of FDA’s line for review. It’s only the fourth time that a drugmaker has won one of these, and it could become the first to be auctioned off. The vouchers were created as an incentive to encourage drug companies to work on medicines for neglected diseases, such as leishmaniasis…” (Hensley, 5/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.